659 related articles for article (PubMed ID: 30878596)
1. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
2. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
3. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
5. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
[TBL] [Abstract][Full Text] [Related]
6. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
7. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
8. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
9. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
11. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
Yang Z; Xu J; Li R; Gao Y; He J
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
14. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
[TBL] [Abstract][Full Text] [Related]
15. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
16. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
17. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
[TBL] [Abstract][Full Text] [Related]
19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
20. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA
Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
